Popular diabetes and weight-loss drugs known as GLP-1s are helping to boost the biopharma sector's return on investment this year, according to a new report from consulting firm Deloitte.

In just a few years, GLP-1s have made quite the name for themselves. Originally prescribed to treat diabetes, these meds really entered the zeitgeist for their notable weight loss side effects.

In a way, the torch is a microcosm of the whole Olympics.’ Ellie Stathaki is the Architecture & Environment Director at Wallpaper*. She trained as an architect at the Aristotle University of ...

Hannah Silver is the Art, Culture, Watches & Jewellery Editor of Wallpaper*. Since joining in 2019, she has overseen offbeat design trends and in-depth profiles, and written extensively across the ...

Wear OS has come a long way since its great revival in 2021, now commanding a fleet of excellent Android smartwatches. While we’re currently on the fifth nominal version of the wearable OS ...

The NBA playoffs start Saturday with four Game 1s, continue Sunday with four more Game 1s and just like that a 16-team, two-month journey will be off and running. “It's the best time of the year ...

Sen. John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of ...

The state is thinking about requiring Medicaid patients who want to use GLP-1s for weight loss to meet a certain number on the body-mass index or try diet and exercise programs or less expensive ...

A new initiative, called "EU OS," has been launched to develop a Linux-based operating system tailored specifically for the public sector organizations of the European Union (EU). This ...

The state is thinking about requiring Medicaid patients who want to use GLP-1s for weight loss to meet a certain number on the body-mass index or try diet and exercise programs or less expensive ...

In addition to obesity and type 2 diabetes, GLP-1s have indications to reduce risk for cardiovascular disease, sleep apnea and kidney disease. Studies show that when these obesity medications are ...